Cargando…

MediQuit, an Electronic Deprescribing Tool for Patients on Polypharmacy: Results of a Feasibility Study in German General Practice

BACKGROUND: Deprescribing is an important task for general practitioners (GPs) in the face of risky polypharmacy. The electronic tool “MediQuit” was developed to guide GPs and patients through a deprescribing consultation that entails a drug-selection phase, shared decision making, and advice on saf...

Descripción completa

Detalles Bibliográficos
Autores principales: Junius-Walker, Ulrike, Viniol, Annika, Michiels-Corsten, Matthias, Gerlach, Navina, Donner-Banzhoff, Norbert, Schleef, Tanja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8342343/
https://www.ncbi.nlm.nih.gov/pubmed/34251594
http://dx.doi.org/10.1007/s40266-021-00861-7
_version_ 1783734047593201664
author Junius-Walker, Ulrike
Viniol, Annika
Michiels-Corsten, Matthias
Gerlach, Navina
Donner-Banzhoff, Norbert
Schleef, Tanja
author_facet Junius-Walker, Ulrike
Viniol, Annika
Michiels-Corsten, Matthias
Gerlach, Navina
Donner-Banzhoff, Norbert
Schleef, Tanja
author_sort Junius-Walker, Ulrike
collection PubMed
description BACKGROUND: Deprescribing is an important task for general practitioners (GPs) in the face of risky polypharmacy. The electronic tool “MediQuit” was developed to guide GPs and patients through a deprescribing consultation that entails a drug-selection phase, shared decision making, and advice on safe implementation. OBJECTIVES: A pilot study was conducted to determine the target group of patients that is selected for consultation and to assess the impact, patient involvement, and feasibility of the tool. METHODS: This was an uncontrolled pilot study. GPs from two German regions were invited to use MediQuit in consultations with a view to deprescribing one drug, if appropriate. They selected patients on the basis of broad inclusion criteria. Collected data entailed participants’ characteristics, patients’ medication lists, deprescribed drugs, and feasibility assessments. Patients were contacted shortly after the consultation and again after 4 weeks. RESULTS: In total, 16 GPs agreed to participate, of whom ten actually performed deprescribing consultations. They selected 41 predominately older patients on excessive polypharmacy. Deprescribing was achieved in 70% of consultations in agreement with patients. Drugs deprescribed were symptom-lowering and preventive drugs (mainly anatomical therapeutic chemical classes A and C). GPs found MediQuit useful in initiating communication on this issue and enhancing deliberations for a deprescribing decision. The median consultation length was 15 min (interquartile range 10–20). At follow-up, GPs and patients infrequently disagreed on which drug(s) was discontinued, and GPs rated patient involvement higher than did patients themselves. DISCUSSION: MediQuit assists in identifying concrete deprescribing opportunities, patient involvement, and shared decision making. The three-step deprescribing procedure is well-accepted once initial organizational efforts are overcome. After revision, further studies are needed to enhance the quality of evidence on acceptance and effectiveness.
format Online
Article
Text
id pubmed-8342343
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-83423432021-08-20 MediQuit, an Electronic Deprescribing Tool for Patients on Polypharmacy: Results of a Feasibility Study in German General Practice Junius-Walker, Ulrike Viniol, Annika Michiels-Corsten, Matthias Gerlach, Navina Donner-Banzhoff, Norbert Schleef, Tanja Drugs Aging Original Research Article BACKGROUND: Deprescribing is an important task for general practitioners (GPs) in the face of risky polypharmacy. The electronic tool “MediQuit” was developed to guide GPs and patients through a deprescribing consultation that entails a drug-selection phase, shared decision making, and advice on safe implementation. OBJECTIVES: A pilot study was conducted to determine the target group of patients that is selected for consultation and to assess the impact, patient involvement, and feasibility of the tool. METHODS: This was an uncontrolled pilot study. GPs from two German regions were invited to use MediQuit in consultations with a view to deprescribing one drug, if appropriate. They selected patients on the basis of broad inclusion criteria. Collected data entailed participants’ characteristics, patients’ medication lists, deprescribed drugs, and feasibility assessments. Patients were contacted shortly after the consultation and again after 4 weeks. RESULTS: In total, 16 GPs agreed to participate, of whom ten actually performed deprescribing consultations. They selected 41 predominately older patients on excessive polypharmacy. Deprescribing was achieved in 70% of consultations in agreement with patients. Drugs deprescribed were symptom-lowering and preventive drugs (mainly anatomical therapeutic chemical classes A and C). GPs found MediQuit useful in initiating communication on this issue and enhancing deliberations for a deprescribing decision. The median consultation length was 15 min (interquartile range 10–20). At follow-up, GPs and patients infrequently disagreed on which drug(s) was discontinued, and GPs rated patient involvement higher than did patients themselves. DISCUSSION: MediQuit assists in identifying concrete deprescribing opportunities, patient involvement, and shared decision making. The three-step deprescribing procedure is well-accepted once initial organizational efforts are overcome. After revision, further studies are needed to enhance the quality of evidence on acceptance and effectiveness. Springer International Publishing 2021-07-12 2021 /pmc/articles/PMC8342343/ /pubmed/34251594 http://dx.doi.org/10.1007/s40266-021-00861-7 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research Article
Junius-Walker, Ulrike
Viniol, Annika
Michiels-Corsten, Matthias
Gerlach, Navina
Donner-Banzhoff, Norbert
Schleef, Tanja
MediQuit, an Electronic Deprescribing Tool for Patients on Polypharmacy: Results of a Feasibility Study in German General Practice
title MediQuit, an Electronic Deprescribing Tool for Patients on Polypharmacy: Results of a Feasibility Study in German General Practice
title_full MediQuit, an Electronic Deprescribing Tool for Patients on Polypharmacy: Results of a Feasibility Study in German General Practice
title_fullStr MediQuit, an Electronic Deprescribing Tool for Patients on Polypharmacy: Results of a Feasibility Study in German General Practice
title_full_unstemmed MediQuit, an Electronic Deprescribing Tool for Patients on Polypharmacy: Results of a Feasibility Study in German General Practice
title_short MediQuit, an Electronic Deprescribing Tool for Patients on Polypharmacy: Results of a Feasibility Study in German General Practice
title_sort mediquit, an electronic deprescribing tool for patients on polypharmacy: results of a feasibility study in german general practice
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8342343/
https://www.ncbi.nlm.nih.gov/pubmed/34251594
http://dx.doi.org/10.1007/s40266-021-00861-7
work_keys_str_mv AT juniuswalkerulrike mediquitanelectronicdeprescribingtoolforpatientsonpolypharmacyresultsofafeasibilitystudyingermangeneralpractice
AT viniolannika mediquitanelectronicdeprescribingtoolforpatientsonpolypharmacyresultsofafeasibilitystudyingermangeneralpractice
AT michielscorstenmatthias mediquitanelectronicdeprescribingtoolforpatientsonpolypharmacyresultsofafeasibilitystudyingermangeneralpractice
AT gerlachnavina mediquitanelectronicdeprescribingtoolforpatientsonpolypharmacyresultsofafeasibilitystudyingermangeneralpractice
AT donnerbanzhoffnorbert mediquitanelectronicdeprescribingtoolforpatientsonpolypharmacyresultsofafeasibilitystudyingermangeneralpractice
AT schleeftanja mediquitanelectronicdeprescribingtoolforpatientsonpolypharmacyresultsofafeasibilitystudyingermangeneralpractice